Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Bagsværd, Denmark,18 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
-
Wegovy® pill showed 21.6% weight loss in early responders and improved mobility in OASIS-4 data at ECO2026.
-
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
-
Novo Nordisk today announced data demonstrating that Wegovy® delivers substantial and consistent weight-loss results for women.
-
Higher-dose Wegovy led to up to 28% weight loss, mainly from fat, with muscle preserved, new trial data show.
-
The strong performance of Wegovy® and continued growth in International Operations have led us to raise our 2026 guidance for both adjusted sales and ...
-
Bagsværd, Denmark, 5 May 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of...
-
Novo Nordisk will present new clinical data and real-world evidence at the European Congress on Obesity, 12–15 May in Istanbul, Turkey.
-
Bagsværd, Denmark, 27 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
-
PIONEER TEENS is the first clinical trial of an oral GLP-1 in children & adolescents 10–17 years with type 2 diabetes, addressing a significant unmet need